Navigation Links
GPhA's 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
Date:8/30/2007

Thurs.-Fri., Sept. 6-7, Mandarin Oriental, Washington, D.C.

ARLINGTON, Va., Aug. 30 /PRNewswire/ -- Three leading generic industry CEOs, along with top Wall Street analysts and key Food and Drug Administration (FDA) and other government officials, will headline the Generic Pharmaceutical Association's (GPhA) Annual Policy Conference on September 6-7, 2007. The conference, "Generics: Prescription for Affordable Health Care," will focus on the legislative, regulatory and business issues that will shape the generic industry in the coming years.

"This conference will look at the wide range of issues affecting the generic industry's efforts to provide consumers with timely access to affordable medicines," said Kathleen Jaeger, GPhA President and CEO. "From regulations to legislation, the industry is facing a series of unique opportunities and challenges."

The conference features keynote presentations from Hospira, Inc. Chairman and CEO Christopher Begley, Mylan Laboratories CEO Robert Coury, and Actavis President and CEO Robert Wessman.

Conference speakers also include U.S. Representatives Henry Waxman (D-CA) and Frank Pallone (D-NJ), FDA Deputy Commissioner Dr. Janet Woodcock, FDA Chief Counsel Sheldon Bradshaw, IMS Health Vice President Doug Long, UBS Warburg Healthcare Banking Director Tommy Erdei, Lehman Brothers Senior Vice President Richard Silver, and Roundtable Healthcare Partners Senior Partner David Koo, among other industry experts. In addition, the conference has special track sessions on federal legislation and legal issues, which will take place on September 6.

GPhA's Annual Policy Conference will be held at the Mandarin Oriental Hotel, 1330 Maryland Avenue, S.W., in Washington, D.C. The conference begins at 8 a.m. on both days. The conference agenda is available online at http://www.gphaonline.org.

For registration information, go to

SOURCE GPhA
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Annual PSA screening reduces risk of prostate cancer deaths
2. Low turnover by Diabetics for free annual checkup
3. UK Spends ?7.3 Billion Annually On Malnutrition Cost
4. Annual Dental Checkups in Children Lagging Behind
5. Annual Budget 2006: Health And Education Sector Receive A Boost
6. Breast cancer survivors slacken on mandated annual mammograms
7. Brazil & Kenya Seek Support For A New Resolution At WHO’s Annual Mee
8. Medical Tourism can Fetch Rs.100 bn Annually by 2012
9. Annual Conference Of Plastic Surgeons In US To Focus On The Future Of Plastic Surgery
10. Jamaica Sees 1000 New Cases of HIV Annually
11. More Indians Die of Rabies Annually
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2008)...ed Spokesperson for Education Campaign on Behalf o...teinase Inhibitor (Human) Augmentation ..., May 17 /PRNewswire/ -- Melissa Biggs, a fashion,...recently named,spokesperson for an education campa...ans to get tested for alpha-1 antitrypsin (AAT) de...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
(Date:5/16/2008)...g Campaign to Emphasize the Importance of Oral and...ire/ -- National dental insurer United,Concordia D...boration,between Oral Health America and the Briti...nce of oral health to overall health. Beginning Ma... States for the first time,making it the largest ...
(Date:5/16/2008)...s chronic disease sufferers gain benefit from calc...(HealthDay News) -- Taking activated vitamin D may... severe chronic kidney disease by about one quarte...tudy of more than 1,400 patients, those being trea...amin D, had their overall risk of death lowered by...
Breaking Medicine News(10 mins):Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...may be the cause of migraines and severe headaches...dy mass //index on frequency, and severity of head...adaches are more common in obese people than those...ers had taken the physical history of the particip...
...ts have found out that increased calcium intake by...may increase the risk of Parkinson’s disease. Park...m. Some of its symptoms are muscle tremors, muscle...ty, stooped posture, slow voluntary movements, and...
...ug AVP-923 is all set to provide relief to people ...clerosis, said the researchers from University of ...s is a chronic neurological disease of the central...he brain and spinal cord and medication till date ...
...was undertaken to find out how to elevate the func...rom arthritis // by the researchers of Feinberg Sc...e study of age 65 yrs and old with arthritis. Func...y to do tasks pertaining to daily living and speci...
Other Medicine News:
(Date:5/15/2008)...acy Clinical Data from Prostate, Colorectal and Ov...Company to Hold Investor Event on Sun., June 1 wit..., May 15 /- Poniard,Pharmac...al company focused,on oncology, today announced th...al trials of picoplatin, in various tumor types an...
(Date:5/15/2008)...ctions demonstrated in Blacks, Hispanics/Latinos, ...dividuals, PARSIPPANY, N.J., May 15 /PRNewswire/ ... presented at the American Society of,Hypertension...08) in New,Orleans demonstrated that the powerful ...an medoxomil) safely and effectively helped,patien...
(Date:5/15/2008).../- CenterWatch, a publishing and,info...h about clinical,trials, finds that investigative ...ic data capture) systems. More than 75% of respond... they had been trained on three or more,EDC system...ctiveness of,their EDC training had improved., St...
(Date:5/15/2008)...ected soon after CEA Trial data reports in third q...RANCISCO, May 15 /- VIA Pha...gy company focused on the development of,compounds...unced today that,it has completed patient enrollme... ACS study is one of three Phase 2 trials investig...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Lotus Blossom Consulting Announces E Book on Infertility Treatment Financing 5637 1Lotus Blossom Consulting Announces E Book on Infertility Treatment Financing 5637 2A maternal link to Alzheimers disease 5633 1A maternal link to Alzheimers disease 5633 2A maternal link to Alzheimers disease 5633 3Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 1Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 2Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diab 770 3Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 1Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 2Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS 28R 29 28pioglitazone HCl 29 Slowed t 766 3
...SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX...dministration (FDA) has,approved the Company,s Inv...inical development of MyocondaR to treat patients ...vium spp,paratuberculosis (MAP). , ,The Company un...,first therapy to be submitted to the FDA for this...
... ROCKVILLE, Md., April 18, 2007--Due to water dama...en forced to change the,location for the upcoming ...l 24, 2007 to discuss new drug application for,mar... to be held at,the FDA, Center for Drug Evaluation...Room, 5630 Fishers Lane, in Rockville, MD, the,mee...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting 2
...S solution tricompartmental total knee prosthesis ...roplasty. State-of-the-art design and manufacturin...optimum biomechanical function as well as a favora...ene tibial insert to keep wear to a minimum. The i...
...knee system was designed for patients with difficu...ons needed custom designs to repair difficult anat... Factor' which reduces the chance of dislocation i...tation has been streamlined and updated so that th...
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively.
...S Solution tricompartmental total knee prosthesis ...roplasty. State-of-the-art design and manufacturin...optimum biomechanical function as well as a favora...ene tibial insert to keep wear to a minimum. The i...
Medicine Products: